Prestige Consumer Healthcare Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ronald Lombardi
- Full Time Employees
- 890
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 660 White Plains Road Tarrytown NY United States of America 10591
- IPO Date
- Feb 10, 2005
- CIK
- 0001295947
- Website
- prestigebrands.com
- Similar Companies
- Business
- Prestige Consumer Healthcare Inc. (NYSE: PBH) develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products and select household cleaning items to retailers across North America and select international markets; its portfolio spans digestive care including Beano, Phazyme, Tagamet, Fleet, and Bacid; eye, ear, nose, and throat remedies such as Clear Eyes, Chloraseptic, Luden's throat lozenges, Debrox, NasalCrom, and Murine; pain relief options like BC Powder and Goody's Headache Powder; oral care products including Efferdent and DenTek; pediatric care with PediaCare, Little Remedies, Boudreaux's Butt Paste, and Nix lice treatments; skin care featuring Compound W wart removal; sleep aids; women's health comprising Monistat yeast infection treatments and Summer's Eve feminine hygiene; and household cleaners such as Spic and Span and Comet. Founded in 1996 through the merger of Medtech Products, Prestige Brands International, and Spic and Span, the company is headquartered in Tarrytown, New York, with a manufacturing facility in Lynchburg, Virginia, and additional operations in the United States, Canada, Australia, and other regions. In fiscal 2026, Prestige entered a definitive agreement to acquire Pillar5 Pharma Inc., a sterile ophthalmic manufacturer and key supplier for Clear Eyes, from Anjac SAS for approximately $150 million in a cash-funded deal expected to close in the third fiscal quarter, enhancing vertical integration, securing 90% in-house manufacturing for eye care and related products, and enabling expansion into OTC men's health via Anjac's men's grooming capabilities including hair loss, skin care, and stress management innovations; the transaction remains roughly EPS-neutral while bolstering supply chain resilience amid robust Clear Eyes demand.
Company News
Premium Brands (TSE:PBH) Reaches New 52-Week Low – Here’s What Happened
PBH or NEOG: Which Is the Better Value Stock Right Now?
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference
Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test
PBH vs. SYK: Which Stock Is the Better Value Option?
Nearly 40,000 eye drops recalled nationwide over possible contamination
Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts
PBH or SYK: Which Is the Better Value Stock Right Now?
Premium Brands Q2 Earnings Call Highlights
California State Teachers Retirement System Has $3.40 Million Position in Prestige Consumer Healthcare Inc. $PBH
Prestige Consumer Healthcare Q1 Earnings Call Highlights
Prestige Consumer Healthcare Inc. (PBH) Q1 2027 Earnings Call Transcript
Prestige Consumer Healthcare (PBH) Q1 Earnings and Revenues Surpass Estimates
Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results
Prestige Consumer Healthcare Inc. $PBH Shares Sold by Bank of New York Mellon Corp
Dimensional Fund Advisors LP Acquires 91,710 Shares of Prestige Consumer Healthcare Inc. $PBH
Ariel Small/Mid Cap Value Q2 2026 Portfolio Activity
Fifth Third Bancorp Purchases 28,699 Shares of Prestige Consumer Healthcare Inc. $PBH
Bessemer Group Inc. Acquires 64,760 Shares of Prestige Consumer Healthcare Inc. $PBH